Financial News

My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by KalVista Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 6 Next >
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback